Rehan Mujahid, DO
Allergy · Wind Gap, PANPI 1962822072
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,946 of the $16,482 with a category attached, or 84.6%. 24 manufacturers reported payments, led by Sanofi at 28.8% of the total. 2025 is the largest year on record at $6,504, more than ten times the $250 reported in 2020.
Across 456 payments — averaging $36.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$5K
- AstraZeneca$3K
- CSL Behring$2K
- GSK$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Biocryst US Sales Co., LLC$644
- plus $4K from 18 others
What the payments were for
- Speaking & faculty fees$2,31214%
- Food & beverage$13,94685%
- Education$2241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 61 | $4,754 |
| AstraZeneca | 71 | $2,763 |
| CSL Behring | 53 | $1,919 |
| GSK | 39 | $1,368 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $1,280 |
| Biocryst US Sales Co., LLC | 30 | $644 |
| Pharming Healthcare, Inc. | 19 | $624 |
| Regeneron Healthcare Solutions, Inc. | 21 | $537 |
| Amgen | 16 | $484 |
| Optinose US, Inc. | 20 | $433 |
| Grifols USA, LLC | 20 | $359 |
| Genentech USA, Inc. | 8 | $198 |
| Octapharma USA, Inc. | 9 | $183 |
| Aimmune Therapeutics, Inc. | 7 | $156 |
| Novartis | 8 | $151 |
| Kaleo, Inc. | 9 | $140 |
| Pfizer | 6 | $120 |
| Blueprint Medicines Corporation | 1 | $101 |
| Hikma Pharmaceuticals USA | 5 | $89 |
| Alk-abello, Inc | 3 | $60 |
| Ionis Pharmaceuticals, Inc. | 2 | $52 |
| Phadia US Inc. | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| LEO Pharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,482 in reported general payments places this provider in the 85th percentile of 25 allergy providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 19 | $52,657 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $24,359 |
| Epinephrine | 41 | $7,289 |
| Arnuity ElliptaFluticasone Furoate | 22 | $5,785 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $2,232 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $1,971 |
| Azelastine Hcl | 64 | $1,379 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 11 | $961 |
| Ipratropium Bromide | 29 | $580 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $567 |
| Fluticasone Propionate | 27 | $323 |
| Montelukast Sodium | 25 | $223 |
| Prednisone | 37 | $181 |
| Famotidine | 11 | $66 |
| Azithromycin | 11 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta | $1,368 | $30,14447 claims |
| Hikma Pharmaceuticals USAEpinephrine | $89 | $7,28941 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 25 allergy providers in Pennsylvania.
Other allergy in Wind Gap
- Michael PalumboPittsburgh$561K
- James DeangeloPittsburgh$79K
- Shannon KearneyBethlehem$48K
- Schweta ArakaliAllentown$12K
- Michelle WeissYork$7K
- David MillerPittsburgh$7K
- Andrew MurphyWest Chester$6K
- Victoria CorreaDoylestown$3K
- Thomas MakinWexford$3K
- Neil FeldmanAllentown$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.